BioPharmSignal logoBioPharmSignal

Biotech News

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind (MNKD)MannKindPartnership

The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI United Therapeutics plans to be the primary manufacturer of ralinepag DPI MannKind

Open original release

Related news

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

ALGSAligos Therapeutics2026-04-16 10:00 EST

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

MNKDMannKind2026-02-18 14:00 EST

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

MLYSMineralys Therapeutics2026-06-03 10:00 EST

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

PMCBPharmaCyte Biotech2025-09-02 13:20 EST

PharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency Applications

MLYSMineralys Therapeutics2026-03-09 20:30 EST

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

View all latest news

MannKind

MannKind is a specialty pharmaceutical company best known for Afrezza and inhaled therapeutic delivery. The company has worked to build a broader inhaled-platform story around respiratory and diabetes care.

Recent company news

MNKDMannKind2026-06-03 10:05 EST

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MNKDMannKind2026-05-29 18:00 EST

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

MNKDMannKind2026-05-29 16:30 EST

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MNKDMannKind2026-05-27 20:00 EST

MannKind to Present at Jefferies Global Healthcare Conference

MNKDMannKind2026-05-27 13:05 EST

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

Stock data

Close
3.95 USD
Market cap
1.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States